Intranasal dexmedetomidine in elderly subjects with or without beta blockade: a randomised double-blind single-ascending-dose cohort study.
Sign Up to like & getrecommendations! Published in 2020 at "British journal of anaesthesia"
DOI: 10.1016/j.bja.2019.12.025
Abstract: BACKGROUND The aim of this double-blind, placebo-controlled, single-ascending-dose study was to determine the safety and tolerability of intranasal dexmedetomidine in the elderly. METHODS We randomly assigned 48 surgical patients ≥65 yr of age to receive… read more here.
Keywords: double blind; intranasal dexmedetomidine; dexmedetomidine elderly; single ascending ... See more keywords
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2021.04.034
Abstract: OBJECTIVE We reviewed our institutional data to evaluate toxicity and efficacy outcomes of pembrolizumab/lenvatinib in recurrent endometrial cancer in a "real-world" clinical setting and to compare the impact of reduced lenvatinib starting dose on outcomes.… read more here.
Keywords: recurrent endometrial; recommended reduced; toxicity; endometrial cancer ... See more keywords
Smaller but more frequent dosing of cefepime in the treatment of febrile neutropenia
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221080078
Abstract: Background Generally national guidelines for febrile neutropenia recommend treatment with cefepime 2 g every 8 h. Due to beta-lactam’s time dependent killing effects, it is hypothesized smaller doses given more frequently might be non-inferior. The objective of… read more here.
Keywords: time; dose cohort; cefepime; cefepime every ... See more keywords